Senate hearing addresses need for more rapid medical innovation

The Senate Health, Education, Labor and Pensions Committee held its first hearing on advancing medical innovation on March10.

Committee Chair Sen. Lamar Alexander noted there is no real political bipartisanship on this issue so it is “an area we ought to succeed in. Every member of this committee is interested in identifying what we can do to make it easier to go from discovery through to the medicine cabinet.”

Discoveries supported by the National Institutes of Health (NIH) can take 10 or 12 years just to get to the FDA’s front door, he said. “And the average cost to get a single drug from the laboratory through the approval process to the medicine cabinet is, according to some estimates, about $1 billion. Other estimates say it’s double that or even more.”

Alexander cited President Obama’s precision medicine initiative and the House 21st Century Cures effort as evidence of interest and momentum in this area.

NIH Director Francis Collins, MD, testified that the organization plans to launch a national initiative with a million or more volunteers that would help researchers find ways to prevent chronic disease. "This venture will pioneer a new model for doing science that emphasizes engaged participants, technologically advanced collection of many different data types, responsible data sharing, and privacy protection," Collins said.

FDA Commissioner Margaret A. Hamburg, MD, also testified, saying the organization has done more in approving new drugs than at another time in history. "This past calendar year, FDA approved 51 novel drugs and biologics, the most in almost 20 years. Today, FDA’s average drug review times are consistently faster than other advanced regulatory agencies around the world, providing Americans earlier access to new, innovative drugs than patients in any other country."

 

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”